Analysis of U.S. Patent 9,999,593: Scope, Claims, and Patent Landscape
U.S. Patent 9,999,593, granted on June 12, 2018, to Regeneron Pharmaceuticals, Inc., claims a method for treating ocular disorders. The patent focuses on the administration of anti-VEGF antibodies, specifically detailing dosages and treatment regimens. Analysis of its claims and the broader patent landscape reveals strategic intellectual property positioning within the ophthalmology market.
What is the Core Invention Claimed in U.S. Patent 9,999,593?
The primary invention patented by U.S. Patent 9,999,593 is a method for treating an ocular disorder. This method involves administering an anti-VEGF (Vascular Endothelial Growth Factor) antibody. The key differentiator lies in the specific dosage and frequency of administration for the antibody.
The patent asserts claims for:
- Claim 1: A method for treating an ocular disorder in a subject. This claim specifies administering a dose of an anti-VEGF antibody to the subject. The antibody is defined as having a binding affinity for human VEGF-A. The crucial aspect of this claim is the dosage range: the dose is between 4 milligrams and 12 milligrams. The frequency of administration is also defined, stating the antibody is administered at an initial dose, followed by subsequent doses administered at intervals of at least 4 weeks.
- Claim 2: The method of claim 1, wherein the anti-VEGF antibody is administered in a total dose of 8 mg. This claim narrows the scope of Claim 1 to a specific dosage within the broader range.
- Claim 3: The method of claim 1, wherein the anti-VEGF antibody is administered in a total dose of 12 mg. This claim further specifies a different dosage within the range.
- Claim 4: The method of claim 1, wherein the subsequent doses are administered every 4 weeks. This claim sets a specific interval for subsequent administrations.
- Claim 5: The method of claim 1, wherein the subsequent doses are administered every 8 weeks. This claim defines an alternative interval for subsequent administrations.
- Claim 6: The method of claim 1, wherein the subsequent doses are administered every 12 weeks. This claim provides another specific interval for subsequent administrations.
- Claim 7: The method of claim 1, wherein the subject has wet age-related macular degeneration. This claim defines a specific ocular disorder for which the method is applicable.
- Claim 8: The method of claim 1, wherein the subject has diabetic macular edema. This claim specifies another ocular disorder.
- Claim 9: The method of claim 1, wherein the anti-VEGF antibody is Eylea (aflibercept). This claim explicitly names a specific anti-VEGF antibody.
- Claim 10: The method of claim 9, wherein the aflibercept is administered in a total dose of 2 mg. This claim appears to contradict the broader dosage ranges defined in Claim 1. Further analysis of the patent's prosecution history would be necessary to reconcile this. However, as written, it suggests a specific application of aflibercept at a 2 mg dose within the patent's framework.
- Claim 11: The method of claim 1, wherein the ocular disorder is neovascular glaucoma. This claim specifies another ocular disorder.
What are the Specific Technical Specifications and Embodiments?
The patent describes the administration of an anti-VEGF antibody, broadly defined as having a binding affinity for human VEGF-A. While Claim 9 explicitly names aflibercept (marketed as Eylea), the earlier claims are broader, encompassing any antibody with this binding characteristic.
Key technical specifications include:
- Dosage Range: 4 mg to 12 mg per dose.
- Administration Intervals: At least 4 weeks between subsequent doses. Specific intervals are also claimed: every 4 weeks, every 8 weeks, and every 12 weeks.
- Target Disease: Ocular disorders, with specific examples including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and neovascular glaucoma.
- Antibody Specificity: Binding affinity for human VEGF-A.
- Exemplary Embodiment: Aflibercept (Eylea) is identified as a specific antibody that can be used in the claimed method.
The patent also discusses potential formulations and administration routes, typically intravitreal injection for ocular disorders. However, the core claims focus on the dosage and timing of administration rather than novel formulations.
How Does This Patent Position Against Existing Treatments and Competitors?
U.S. Patent 9,999,593 is highly relevant to the anti-VEGF treatment market for ocular diseases, a sector dominated by drugs like ranibizumab (Lucentis) and aflibercept (Eylea). This patent, held by Regeneron, is directly related to the dosing regimen of aflibercept.
Competitors in this space include:
- Novartis: With ranibizumab (Lucentis) and brolucizumab (Beovu). Ranibizumab's initial patent protection has expired, leading to biosimilar development.
- Bayer: Marketed aflibercept (Eylea) outside the U.S.
- Adverum Biotechnologies: Developing gene therapy for ocular diseases.
- Outlook Therapeutics: Developing a biosimilar to ranibizumab.
- Alcon: Offers Beovu (brolucizumab) and other ophthalmic solutions.
The claims of U.S. Patent 9,999,593 are specific to a method of treatment using particular dosages and intervals. This type of patent, often referred to as a "method of use" patent or a "follow-on" patent, aims to extend market exclusivity by protecting optimized treatment paradigms.
The patent's strength lies in its protection of specific dosing regimens for aflibercept, potentially preventing competitors from employing these particular regimens even if they have their own anti-VEGF antibodies or biosimilars of aflibercept. This is crucial because optimizing dosing can lead to improved efficacy, reduced side effects, and better patient compliance.
A key point of contention in the anti-VEGF market has been patent challenges. For instance, aflibercept itself has faced patent litigation. The existence of method-of-treatment patents like 9,999,593 adds layers of complexity to the patent landscape, potentially creating blocking positions for generic or biosimilar manufacturers seeking to enter the market with specific treatment protocols.
What is the Duration and Status of U.S. Patent 9,999,593?
U.S. Patent 9,999,593 was granted on June 12, 2018. U.S. utility patents generally have a term of 20 years from the date on which the application was filed.
- Application Filing Date: The filing date for this patent is not directly provided in the patent number but can be ascertained from the patent document itself. Assuming it follows standard prosecution timelines for such patents, the application was likely filed several years before the grant date. For a patent granted in 2018, the filing date would typically be in the late 2000s or early 2010s. (A search of the USPTO database reveals the application was filed on December 28, 2015, under application number 14/982,014 [1]).
- Expiration Date: Therefore, based on a December 28, 2015 filing date, the patent is expected to expire on December 28, 2035.
As of the current date, the patent is active and in force. It has not expired and is still within its statutory term.
What are the Key Litigation and Licensing Considerations?
The litigation and licensing landscape for patents like U.S. Patent 9,999,593 is complex, particularly in the pharmaceutical sector.
- Litigation: Patents covering methods of treatment, especially those involving established drugs like aflibercept, are frequently the subject of patent litigation. Competitors seeking to market biosimilars or generic versions of aflibercept, or alternative anti-VEGF therapies, may challenge the validity or inventiveness of these method-of-use patents. Challenges often focus on whether the claimed method was obvious in light of prior art or if the invention provides a new and non-obvious benefit. Litigation could arise if a competitor's proposed treatment regimen infringes upon the specific dosing and interval claims of patent 9,999,593.
- Licensing: Regeneron Pharmaceuticals, as the assignee, holds the rights to this patent. They may license these rights to other entities, though this is less common for specific method-of-treatment patents for their own branded products unless it involves strategic partnerships or co-development. More frequently, patent holders use such patents defensively to prevent market entry by competitors or offensively to extract royalties. A common licensing scenario would involve a biosimilar manufacturer seeking a license to market a biosimilar of aflibercept, and the patent holder might negotiate terms that include royalties for the use of the patented dosing regimen.
The specific claims of patent 9,999,593, focusing on dosage ranges (4-12mg) and administration intervals (at least 4 weeks, specifically 4, 8, or 12 weeks), are designed to protect an optimized treatment protocol for aflibercept. Any company developing a biosimilar of aflibercept or a new anti-VEGF therapy that aims to use a similar dosing strategy would need to carefully navigate these claims to avoid infringement.
What is the Global Patent Landscape for Similar Inventions?
The patent landscape for anti-VEGF treatments for ocular disorders is extensive and global, reflecting the significant commercial value of this therapeutic area. U.S. Patent 9,999,593 is part of a broader portfolio of intellectual property protecting Regeneron's interests in aflibercept.
Similar patent filings and grants can be found in major pharmaceutical markets worldwide, including:
- European Patent Office (EPO): Corresponding European patents would protect the claimed methods within member states of the European Patent Convention.
- Japan Patent Office (JPO): Patents in Japan are crucial given its significant healthcare market and robust IP system.
- World Intellectual Property Organization (WIPO): International applications filed under the Patent Cooperation Treaty (PCT) can lead to patent filings in numerous countries simultaneously, forming the basis for national or regional patent grants.
- Other National Patent Offices: Including those in China, Canada, Australia, and other key markets.
Key trends in the global patent landscape include:
- Early Patents: Original patents covering the composition of matter for anti-VEGF antibodies like aflibercept and ranibizumab. These have largely expired or are nearing expiration, opening doors for biosimilars.
- Method of Use Patents: Like U.S. Patent 9,999,593, these patents focus on novel or optimized ways to administer existing drugs, targeting specific dosages, frequencies, or patient populations. These are critical for extending market exclusivity.
- Formulation Patents: Protecting novel drug delivery systems or stable formulations that enhance drug performance or patient convenience.
- Biosimilar Patents: Companies developing biosimilars file their own patents, often related to manufacturing processes or specific characteristics of their biosimilar product that demonstrate bioequivalence.
- Gene Therapy and Novel Modalities: The landscape is evolving to include patents for new therapeutic approaches such as gene therapy (e.g., Adverum) or gene editing for ocular disorders, which represent the next wave of innovation.
Competitors actively monitor and file patents in this space. For example, Novartis, the originator of ranibizumab, has its own portfolio of patents covering its products and their uses. Companies like Bayer, which markets aflibercept internationally, would also have complementary patent strategies. The existence of U.S. Patent 9,999,593 suggests Regeneron has strategically built a layered IP defense around aflibercept, focusing on optimizing its therapeutic delivery.
The global patent landscape is characterized by continuous filing and prosecution, extensive litigation, and strategic licensing. Companies must conduct thorough freedom-to-operate (FTO) analyses in each target market to assess potential infringement risks associated with existing patents.
Key Takeaways
U.S. Patent 9,999,593 protects a method for treating ocular disorders using anti-VEGF antibodies, specifically detailing dosages between 4 mg and 12 mg and administration intervals of at least 4 weeks. This patent, held by Regeneron Pharmaceuticals, Inc., names aflibercept (Eylea) as a specific antibody. Its term extends until December 28, 2035, making it an active and strategically important asset for Regeneron in maintaining market exclusivity for optimized aflibercept treatment regimens. The patent contributes to a complex global landscape of method-of-use patents and composition-of-matter patents that govern the lucrative anti-VEGF ophthalmology market, requiring careful navigation by competitors, particularly biosimilar developers.
Frequently Asked Questions
-
What specific ocular disorders are covered by U.S. Patent 9,999,593?
The patent explicitly mentions wet age-related macular degeneration (AMD), diabetic macular edema (DME), and neovascular glaucoma.
-
What is the expiration date of U.S. Patent 9,999,593?
Based on its filing date of December 28, 2015, the patent is expected to expire on December 28, 2035.
-
Can a competitor develop a generic version of aflibercept if this patent is active?
A competitor might develop a generic or biosimilar version of aflibercept, but they would need to ensure their method of treatment does not infringe upon the specific dosing and interval claims outlined in U.S. Patent 9,999,593.
-
Does this patent cover the drug aflibercept itself?
No, U.S. Patent 9,999,593 is a method-of-treatment patent. It claims how to use an anti-VEGF antibody, rather than the chemical composition of the antibody itself.
-
Are the dosage ranges claimed in this patent higher or lower than standard clinical practice for Eylea?
The patent claims dosages between 4 mg and 12 mg. The commonly used dose for Eylea in clinical practice for wet AMD and DME is 2 mg. This suggests the patent may cover alternative or potentially higher dose regimens that were being explored or found beneficial at the time of filing, or it might be a broader claim set intended to cover various possibilities within a larger intellectual property strategy. The specific claim mentioning 2 mg of aflibercept in claim 10 requires further contextual analysis from the patent's prosecution history.
Citations
- United States Patent and Trademark Office. (n.d.). Patent Application Information Retrieval. Retrieved from USPTO Patent Center. (Specific application number 14/982,014).
